United Therapeutics (UTHR) Reports In-Line Q4 EPS, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $601.32 --0%
Financial Fact:
Net income per diluted common share (in dollars per share): 3.5
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Net income per diluted common share (in dollars per share): 3.5
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $3.89, in-line with the analyst estimate of $3.89. Revenue for the quarter came in at $464.7 million versus the consensus estimate of $420.9 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Reservoir Media, Inc. (RSVR) Tops Q2 EPS by 2c; offers guidance
- Harmony Biosciences (HRMY) Misses Q3 EPS by 30c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
